Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Valacyclovir on Synapse: Tips and Tricks for Better Search Results
18 February 2024
Valacyclovir Hydrochloride, sold under the brand name Valtrex, is an antiviral drug that was first approved in the USA in 1995.
Read →
Positive Outcome for Henlius Phase 1 HLX14 Trial Confirmed
Latest Hotspot
3 min read
Positive Outcome for Henlius Phase 1 HLX14 Trial Confirmed
11 February 2024
Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.
Read →
Strategically Search Dicyclomine on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Dicyclomine on Synapse: A How-to Guide
11 February 2024
Dicyclomine Hydrochloride, sold as BENTYL, is an antispasmodic and anticholinergic drug. Introduced in 1950 for Irritable Bowel Syndrome treatment in the US, it has now been removed from the market.
Read →
Pliant Therapeutics Reports Favorable Phase 2a Trial Outcomes for Bexotegrast in Liver Fibrosis Suspected Cases
Latest Hotspot
3 min read
Pliant Therapeutics Reports Favorable Phase 2a Trial Outcomes for Bexotegrast in Liver Fibrosis Suspected Cases
11 February 2024
Pliant Therapeutics Reports Positive Phase 2a INTEGRIS-PSC Trial Results for Bexotegrast in Primary Sclerosing Cholangitis with Suspected Liver Fibrosis.
Read →
User-friendly Guide to Find Oxycodone on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Oxycodone on Synapse
11 February 2024
Oxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain.
Read →
Acepodia Gets US Approval for Innovative Anti-EGFR Cell Therapy Trial, ACE2016
Latest Hotspot
3 min read
Acepodia Gets US Approval for Innovative Anti-EGFR Cell Therapy Trial, ACE2016
11 February 2024
Acepodia Reveals US Regulatory Approval for Pioneering Anti-EGFR Allogeneic Cell Treatment Trial, Designated as ACE2016.
Read →
Harnessing Synapse for Diazepam Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Diazepam Information: Strategies and Tips
11 February 2024
Diazepam, a significant GABAA receptor agonist approved by Waylis in 1963, effectively treats conditions like muscle spasticity, alcohol withdrawal, anxiety disorders, and epilepsy.
Read →
EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
Latest Hotspot
3 min read
EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
11 February 2024
Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.
Read →
Effortless Searching: How to Find Methylphenidate on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Methylphenidate on Synapse
11 February 2024
Methylphenidate hydrochloride is a leading CNS stimulant, first approved by the US on December 5, 1955, and developed by Novartis. It effectively treats narcolepsy, ADD, and ADHD.
Read →
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
Latest Hotspot
3 min read
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
11 February 2024
4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.
Read →
Making the Most Out of Synapse: Searching for Carvedilol
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Carvedilol
11 February 2024
Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.
Read →
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
Latest Hotspot
3 min read
Inmagene Activates Its Right to Secure Sole Global Licensing for IMG-007 and IMG-004 from HUTCHMED
11 February 2024
Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.
Read →